CCHT(SZ:000661) Shang Hai Zheng Quan Bao·2026-02-24 17:07Core Viewpoint - The announcement highlights that Changchun High-tech Industry (Group) Co., Ltd.'s subsidiary, GenSci Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of GenSci141 ointment, which is aimed at treating specific conditions related to male genital development [1][2]. Group 1: Drug Information - The product name is GenSci141 ointment, which is a dihydrotestosterone ointment classified as a chemical drug of categories 2.2 and 2.4 [2]. - The clinical trial application was approved under acceptance numbers CXHL2501394, CXHL2501395, CXHL2501396, and CXHL2501397 [1]. - The ointment is intended for conditions such as hypogonadotropic hypogonadism, 5α-reductase type 2 deficiency, congenital adrenal hyperplasia, and idiopathic causes leading to penile underdevelopment in children [1][2]. Group 2: Market Context - Current treatment methods for penile underdevelopment in children include medication, surgery, and psychological counseling, with medication being the primary approach [2]. - There has been no approved medication specifically for improving penile development in children until now, indicating a potential market opportunity for GenSci141 ointment [2]. Group 3: Company Strategy - The company plans to actively advance the research and development of the GenSci141 ointment and will adhere to relevant regulations for timely information disclosure regarding the project's progress [4].